---
document_datetime: 2025-12-22 14:59:36
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zemcelpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zemcelpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1605289
conversion_datetime: 2025-12-28 11:38:49.197977
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zemcelpro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 22/12/2025                          |                                             | SmPC,                            | To update the SmPC by correcting the Leukopenia |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316958   | PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update the SmPC by correcting the Leukopenia percentage in Section 4.8 and the data for Acute Lymphoid Leukaemia and Myelodysplastic Syndrome in Section 5.1. In addition, the MAH took the opportunity to implement editorial changes to (1) update the MAHs phone number in the Annexes, (2) correct a translation error in   | Labelling and PL   | percentage in Section 4.8 and the data for Acute Lymphoid Leukaemia and Myelodysplastic Syndrome in Section 5.1.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------|